Frequent expression of CD30 in extranodal NK/T‐cell lymphoma: Potential therapeutic target for anti‐CD30 antibody‐based therapy

Publisher： John Wiley & Sons Inc

E-ISSN： 1099-1069|36|1|166-173

ISSN： 0278-0232

Source： Hematological Oncology (Electronic), Vol.36, Iss.1, 2018-02, pp. : 166-173

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Interferon (IFN)- plus bexarotene were effective in the treatment of multi focal, cutaneous, CD30+, large T cell lymphoma

By  

Inpharma, Vol. 1, Iss. 1324, 2002-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

uPAR as Anti-Cancer Target: Evaluation of Biomarker Potential, Histological Localization, and Antibody-Based Therapy

By  

Current Drug Targets, Vol. 12, Iss. 12, 2011-11 ,pp. : 1744-1760

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-CD3 Recombinant Diphtheria Immunotoxin Therapy of Cutaneous T Cell Lymphoma

By  

Current Drug Targets, Vol. 10, Iss. 2, 2009-02 ,pp. : 104-109

Bentham Science Publishers

Access to resources Recommend Favorite

Autologous Peripheral Stem-cell Transplantation after Intensive Chemotherapy in a Case of CD30 (Ki-1)-Positive Anaplastic Large-cell Lymphoma

By Tsuda T   Matsunami M   Nakayama K   Hara J   Sakaguchi R   Katayama N   Okamoto Y   Ota K  

The Journal of International Medical Research, Vol. 29, Iss. 5, 2001-09 ,pp. : 425-431

Field House Publishing

Access to resources Recommend Favorite

Preliminary Experience with Yttrium-90-labelled Rituximab (Chimeric Anti CD-20 Antibody) in Patients with Relapsed and Refractory B Cell Non-Hodgkins Lymphoma

By  

Current Radiopharmaceuticals, Vol. 9, Iss. 2, 2016-08 ,pp. : 160-168

Bentham Science Publishers

Access to resources Recommend Favorite